Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: Evaluation of 1674 cases by tissue microarray

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 2, 2012, Pages 163-171

  Turner, Bradley M ^a   Cagle, Philip T ^b   Sainz, Irma M ^c   Fukuoka, Junya ^d   Shen, Steven S ^b   Jagirdar, Jaishree ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Nacogdoches Memorial Hospital   (United States)

^d TOYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC PROTEINASE; NAPSA PROTEIN, HUMAN; NUCLEAR PROTEIN; THYROID NUCLEAR FACTOR 1; TRANSCRIPTION FACTOR;

ADENOCARCINOMA; ADULT; ARTICLE; DIFFERENTIAL DIAGNOSIS; HUMAN; LUNG; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; PATHOLOGY; SENSITIVITY AND SPECIFICITY; SMALL CELL CARCINOMA;

ADENOCARCINOMA; ADULT; ASPARTIC ACID ENDOPEPTIDASES; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG; LUNG NEOPLASMS; NUCLEAR PROTEINS; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTORS;

EID: 84856617883     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0320-OA     Document Type: Article

References (36)

1. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010;41(1):20-25.
2. Ueno T, Linder S, Elmberger G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer. 2003;88(8):1229-1233.
3. Rosai, J. Respiratory tract: lung and pleura. In: Rosai J, ed. Rosai and Ackerman's Surgical Pathology. 9th ed. St. Louis, Missouri: Mosby Elsevier; 2004: 359-458.
4. Colby TV, Koss MN, Travis WD. Carcinoma of the lung: overview, incidence, etiology and screening. In: Rosai J, Sobin LH, eds. Tumors of the Lower Respiratory Tract. Washington, DC: Armed Forces Institute of Pathology; 1994:91-106.
5. Atlas Tumor of Pathology; 3rd series, fascicle 13.
6. Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol. 2010;5(4):442-447.
7. Rossi A, Maione P, Bareschino MA, et al. The emerging role of histology in the choice of first-line treatment of advanced non-small cell lung cancer: implication in the clinical decision-making. Curr Med Chem. 2010;17(11):1030- 1038.
8. Cagle PT, Allen TC, Dacic S, et al. Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med. 2011;135(1):110-116.
9. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International multidisciplinary lung adenocarcinoma classification. J Thoracic Oncol. 2011;6(2):244-285.
10. Cagle PT, Dacic S. Lung cancer and the future of pathology. Arch Pathol Lab Med. 2011;135(3):293-295.
11. Pavlides, N Briasoules, E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003; 39(14):1990-2005.
12. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004;100(9):1776-1785.
13. Field RW, Smith BJ, Platz CE, et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst. 2004;96(14):1005-1007.
14. Stang A, Pohlabeln H, Muller KM, Jahn I, Giersiepen K, Jockel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006;52(1):29-36.
15. Moreira A, Gonen M, Rekhtman N, Downey R. Progenitor stem cell marker expression by pulmonary carcinomas. Mod Pathol. 2010;23(6):889.895.
16. Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma of the lung. Arch Pathol Lab Med. 2008; 132(3):384-396.
17. Gu K, Shah V, Ma C, Zhang L, Yang M. Cytoplasmic immunoreactivity of thyroid transcription factor-1 (clone 8G7G3/1) in hepatocytes: true positivity or cross reaction? Am J Clin Pathol. 2007;128(3):382-388.
18. Lau SK, Luthringer DJ, Eisen RN. Thyroid transcription factor-1: a review. Appl Immunohistochem Mol Morphol. 2002;10(2):97-102.
19. Dejmek A, Naucler P, Smedjeback A, et al. Napsin A (TAO2) is a useful alternative to thyroid transcription factor-1 (TTF-1) for the identification of pulmonary adenocarcinoma of cells in pleural effusions. Diagn Cytopathol. 2007;35(8):493-497.
20. Dabbs D. Immunohistochemistry of metastatic carcinoma of unknown primary. In: Dabbs DJ, ed. Diagnostic Immunohistochemistry. 2nd ed. Philadelphia, Pennsylvania: Churchill Livingstone Elsevier; 2006:180-226.
21. DiLoreto C, Puglisi F, DiLauro V, Damante G, Fabbro D, Beltrami CA. Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma. J Clin Pathol. 1997;50(1):30-32.
22. DiLoreto C, Puglisi F, DiLauro V, Damante G, Beltrami CA. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. Cancer Lett. 1998;124(1):73-78.
23. Fabbro D, DiLoreto C, Stamerra O, Beltrami CA, Lonigro R, Damante G. TTF-1 gene expression and human lung tumors. Eur J Cancer. 1996;32A(3): 512-517.
24. Bejarno PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor 1 in pulmonary and breast carcinomas. Mod Pathol. 1996;9(4):445-452.
25. Lazzaro D, Price M, DeFelice M, DiLauro. The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the fetal brain. Development. 1991;113(4):1093-1104.
26. Stahlman MT, Gray ME, Whitsett JA. Expression of thyroid transcription factor-1 (TTF-1) and fetal and neonatal human lung. J Histochem Cytochem. 1996;44(7):673-678.
27. Fabbro D, DiLoreto C, Beltrami CA, Belfiore A, DiLauro R, Damante G. Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res; 54(17):4744-4749.
28. Katoh R, Kawaoi A, Miyagi E, et al. Thyroid transcription factor-1 in normal, hyperplastic, and neoplastic follicular thyroid cell examined by immunohistochemistry and nonradioactive in situ hybridization. Mod Pathol; 13(5):570-576.
29. Woischnik M, Bauer A, Aboutaam R, Pamir A, et al. Cathepsin H and napsin A are active in the alveoli and increased in alveolar proteinosis. Eur Respir J. 2008;31(6):1197-1204.
30. Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol. 2010;23(5): 654-661.
31. Brash F, Ochs M, Kahne T, et al. Involvement of napsin A in the C- and Nterminal processing of surfactant protein B in type-II pneumocytes of the human lung. J Biol Chem. 2003;278(49):49006-49014.
32. Suzuki A, Shijubo N, Yamada G, et al. Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinoma from other organs. Pathol Res Pract. 2005;201(8-9):579-586.
33. Hirano T, Gong Y, Yoshida K, et al. Usefulness of TAO2 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer. 2003;41(2):155-162.
34. West RB, Harvell J, Linn SC, et al. Apo D in soft tissue tumors: a novel marker for dermatofibromasarcoma protuberans. Am J Surg Pathol. 2004;28(8), 1063-1069.
35. Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ. 2004; 329(7458):168-169.
36. Campbell SC, Novic AC, Bukowski RM. Renal tumors. In: Wein AJ, ed. Campbell-Walsh Urology. Vol 2. 9th ed. Philadelphia, Pennsylvania: Saunders Elsevier; 2007:1582-1632.